Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29302758 | 1.00 | PREP (0.57) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL27966167 | 0.97 | PREP (0.53) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL8998498 | 0.87 | PREP (0.58) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL8998434 | 0.87 | PREP (0.58) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL19349903 | 0.85 | PREP (0.61) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL9846339 | 0.84 | PREP (0.61) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL29553 | 0.82 | PREP (0.67) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL205223 | 0.82 | PREP (0.67) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL475715 | 0.82 | PREP (0.67) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL29658848 | 0.82 | PREP (0.67) | PREPTSHRL3MBTL1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9254292-B2 | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-09 | — | — | US | disclosed |
| US-8980920-B2 | Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohmn Corp. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120258078-A1 | ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | SCHERING CORPORATION (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120015974-A1 | IMIDAZOPYRIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8063218-B2 | Imidazopyridine inhibitors of IAP | GENENTECH, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110223134-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258078-A1 | ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | HAVCR2, ZC3HAV1, EIF2AK2 | PREP 727/4885TSHR 3704/4885L3MBTL1 2202/4885 |
| US-20120015974-A1 | IMIDAZOPYRIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | PREP 523/4885TSHR 3064/4885L3MBTL1 848/4885 |
| US-20110223134-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | FOXM1, ZC3HAV1L, C1S | PREP 1777/4885TSHR 4559/4885L3MBTL1 105/4885 |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, ZC3HAV1L | PREP 1899/4885TSHR 1617/4885L3MBTL1 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.